Skip to main navigation

Overview
Shareholder Information
Events & Presentations
News
Corporate Governance
IR Contact
- Email Alerts
- Contact IR

News

News

Year

March 17, 2022

Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG

PDF Version

NL

March 7, 2022

Oxurion Successfully Closes EUR >10 Million in Private Placement

PDF Version

March 3, 2022

Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement

PDF Version

NL

February 22, 2022

Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA

PDF Version

NL

February 22, 2022

Oxurion NV announces 2021 Full Year Results and 2022 Outlook

PDF Version

NL

February 14, 2022

Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference

PDF Version

February 11, 2022

Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference

PDF Version

February 8, 2022

Oxurion to Participate in the 2022 BIO CEO and Investor Conference

PDF Version

January 18, 2022

OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference

PDF Version

January 7, 2022

Oxurion Provides Update on Clinical Pipeline Progress

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 21 - 30 of 31

Section Title

Who We Are
THR-149
News & Events
Let’s Talk

Connect with Us

LinkedIn
Twitter

Ⓒ2022 Oxurion NV. All rights reserved.